Ann: Opthea presents Ph1/2a wAMD data at Retina Society Meeting, page-3

"In patients receiving combination OPT-302 + Lucentis®, the proportion gaining ≥5, ≥10 or ≥15 letters of vision from baseline to week 12 was 67%, 44% and 33% respectively in treatment-naïve subjects (baseline mean best corrected visual acuity (BCVA) 56.4 letters) while it was 53%, 16% and 0% for patients previously treated with multiple intravitreal anti-VEGF-A agents (baseline mean BCVA 64.5 letters)"

I'm not sure how to judge their prelim results - Obviously more letters wererestored in the treatment naive group vs groups that previously received Lucentis, but the BCVA was also lower for the treatment naive group (almost 20% lower). One might expect a lower BCVA i.e. a worse eye easier to treat and improve? So which is better?